Initial experience with irreversible electroporation of liver tumours.
Ablation
Colorectal cancer
Hepatocellular carcinoma
Irreversible electroporation
Liver metastases
Nano knife
Journal
European journal of radiology open
ISSN: 2352-0477
Titre abrégé: Eur J Radiol Open
Pays: England
ID NLM: 101650225
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
12
2018
revised:
14
01
2019
accepted:
17
01
2019
entrez:
7
2
2019
pubmed:
7
2
2019
medline:
7
2
2019
Statut:
epublish
Résumé
Thermal ablation of liver tumours is an established technique used in selected patients with relatively small tumours that can be ablated with margin. Thermal ablation methods are not advisable near larger bile ducts that are sensitive to thermal injury causing strictures and severe morbidity. Irreversible electroporation (IRE) has the possibility to treat these tumours without harming the bile tree. The method is relatively new and has been proven to be feasible and safe with promising oncological results. 50 treatments were performed on 42 patients that were not resectable or treatable by thermal ablation (12 women and 30 men) with 59 tumours in total. 51% were colorectal cancer liver metastases (CRCLM) and 34% were hepatocellular carcinomas (HCC). 70% of the treatments were performed using stereotactic CT-guidance for needle placement. 81% of the treatments were performed with initial success. All patients with missed ablations were re-treated. Local recurrence rate at 3 months was 3% and 37% at one year. The complication rate was low with 2 patients having major complications (Clavien-Dindo grade 3b-5) and without 30-day mortality. IRE is safe for treating tumours not suitable for thermal ablation with 63% of patients being without local recurrence after one year in a group of patients with tumours deemed unresectable. IRE has a role in the treatment of unresectable liver tumours close to heat-sensitive structures not suitable for thermal ablation.Level of Evidence: Level 4, Case Series.
Identifiants
pubmed: 30723754
doi: 10.1016/j.ejro.2019.01.004
pii: S2352-0477(19)30003-6
pmc: PMC6351588
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62-67Références
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
pubmed: 17241099
Br J Anaesth. 2009 May;102(5):650-3
pubmed: 19346232
Semin Liver Dis. 2010 Feb;30(1):61-74
pubmed: 20175034
Radiology. 2011 Feb;258(2):351-69
pubmed: 21273519
J Vasc Interv Radiol. 2011 May;22(5):611-21
pubmed: 21439847
J Vasc Interv Radiol. 2011 Sep;22(9):1275-8
pubmed: 21703873
J Surg Oncol. 2013 Apr;107(5):544-9
pubmed: 23090720
Technol Cancer Res Treat. 2013 Jun;12(3):233-41
pubmed: 23369152
Cardiovasc Intervent Radiol. 2014 Feb;37(1):140-6
pubmed: 23636246
Bioelectromagnetics. 2013 Oct;34(7):512-20
pubmed: 23740887
Expert Rev Anticancer Ther. 2014 Aug;14(8):931-45
pubmed: 24746315
J Vasc Interv Radiol. 2014 Aug;25(8):1233-1239.e2
pubmed: 24861662
Eur Radiol. 2014 Oct;24(10):2467-75
pubmed: 24939670
Cardiovasc Intervent Radiol. 2014 Dec;37(6):1523-9
pubmed: 25212418
J Vasc Interv Radiol. 2014 Nov;25(11):1691-705.e4
pubmed: 25442132
J Vasc Interv Radiol. 2015 Aug;26(8):1184-8
pubmed: 26119204
Radiol Clin North Am. 2015 Sep;53(5):933-71
pubmed: 26321447
World J Gastroenterol. 2016 Jan 7;22(1):253-61
pubmed: 26755874
J Vasc Interv Radiol. 2016 Apr;27(4):480-6
pubmed: 26922979
AJR Am J Roentgenol. 2017 Jan;208(1):193-200
pubmed: 27762601
Eur J Surg Oncol. 2017 Apr;43(4):751-757
pubmed: 28109674
Sci Rep. 2017 Mar 07;7:43687
pubmed: 28266600
Radiology. 2017 Sep;284(3):877-886
pubmed: 28453431
J Surg Oncol. 2017 May;115(6):704-710
pubmed: 28493544
Radiology. 2017 Dec;285(3):1023-1031
pubmed: 28799842
Acta Anaesthesiol Scand. 2017 Oct;61(9):1066-1074
pubmed: 28804874
BMC Cancer. 2018 Jan 15;18(1):78
pubmed: 29334918
Eur J Radiol. 2018 Apr;101:72-81
pubmed: 29571804